Form SC 13G Tarsus Pharmaceuticals, Filed by: TimesSquare Capital Management, LLC
- Futures rise as bank fears ebb after Credit Suisse rescue, Fed in focus
- Fed March Meeting Preview: Here's what Wall Street analysts expect from Powell
- First Republic bounces on report of work on wider deposit insurance plan
- Amazon to cut 9,000 jobs at AWS, advertising, Twitch and PXT; analysts positive
- European bank shares rally, bonds battered after Credit Suisse debt wipeout
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of l934
TARSUS PHARAMACEUTICALS INC.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
December 31, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed.
☒ Rule 13d-1(b)
☐ Rule 13d-1(c)
☐ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 87650L103
Names of Reporting Persons
I.R.S. Identification Nos. of Above Persons (Entities Only)
TimesSquare Capital Management, LLC
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
SEC Use Only
Citizenship or Place of Organization
Sole Voting Power
Shared Voting Power
Sole Dispositive Power
Shared Dispositive Power
Aggregate Amount Beneficially Owned by Each Reporting Person
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
Percent of Class Represented by Amount in Row 9
Type of Reporting Person (See Instructions)
Name of Issuer: TARSUS PHARMACEUTICALS, INC.
Address of Issuers Principal Executive Offices: 15440 LAGUNA CANYON ROAD
IRVINE, CALIFORNIA 92618
Name of Persons Filing: TimesSquare Capital Management, LLC (TimesSquare)
Address of Principal Business Office or, if none, Residence:
7 Times Square, 42nd Floor
New York, NY 10036
Citizenship: TimesSquare is a Delaware limited liability company.
Title of Class of Securities: Common Stock, $1.00 par value
CUSIP Number: 87650L103
This statement is filed by TimesSquare pursuant to §§240.l3d-l(b), or 240.13d-2(b) or (c), on the basis that TimesSquare is an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
Ownership. The following ownership information is as of December 31, 2022.
Amount Beneficially Owned: 1,429,310
Percent of Class: 5.36%
Percent of class is based on 26,672,188 shares of Common Stock outstanding as of December 31, 2022 as reported to us by FT Interactive Data Corporation.
Number of shares as to which the person has:
sole power to vote or to direct the vote 1,429,310*
shared power to vote or to direct the vote 0
sole power to dispose or to direct the disposition of 1,429,310*
shared power to dispose or to direct the disposition of 0
All of the shares reported on in this statement are owned by investment advisory clients of TimesSquare. In its role as investment adviser, TimesSquare has voting and dispositive power with respect to these shares.
Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
Ownership of More than Five Percent on Behalf of Another Person.
The shares of Common Stock reported on in this statement are owned by investment advisory clients of TimesSquare, and such clients have the right to receive dividends from and proceeds from the sale of such shares. To TimesSquares knowledge, the interest of no one of these clients relates to more than 5% of the class.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
Identification and Classification of Members of the Group.
Notice of Dissolution of Group.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 3, 2023
TIMESSQUARE CAPITAL MANAGEMENT, LLC
/s/ David M. Cielusniak
|Name/Title:||David M. Cielusniak|
|Chief Compliance Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!